Table 4.
Outcomes of primary endpoint and secondary endpoints from the treatment groups in ITT population
| Outcomes | Treatment | Risk difference (95% CI) | Relative risk (95% CI) | P value | |
| SAP (n=33) | Regular CAS (n=31) | ||||
| Primary endpoint | 0 (0.0) | 3 (9.7) | −9.7 (−20.1 to 0.7) | NA | 0.11 |
| Secondary endpoints | |||||
| HPP | 0 (0.0) | 7 (22.6) | −22.6 (−36.8 to −10.2) | NA | 0.04 |
| Procedure-related adverse events | 1 (3.0) | 2 (6.5) | −3.5 (−13.9 to 6.9) | 0.64 (0.13 to 3.21) | 0.61 |
| Myocardial infarction | 1 (3.0) | 1 (3.2) | −0.2 (−0.86 to 0.82) | 0.97 (0.24 to 3.96) | 1.00 |
| Haemorrhage 30 days to 1 year | 0 (0.0) | 0 (0.0) | NA | NA | 1.00 |
| Death at 30 days | 0 (0.0) | 0 (0.0) | NA | NA | 1.00 |
| Stroke resulting in deformity | 0 (0.0) | 0 (0.0) | NA | NA | 1.00 |
CAS, carotid artery stenting; HPP, hyperperfusion phenomenon; ITT, intent-to-treat; SAP, staged angioplasty.